Gluteus Maximus Transfer for Hip Abductor Insufficiency Following Total Hip Arthroplasty
Clinical and Functional Outcomes of Gluteus Maximus Transfer for the Management of Hip Abductor Insufficiency Following Total Hip Arthroplasty: A Clinical Study
Hip abductor insufficiency is a challenging complication following total hip arthroplasty (THA). It may result from damage to the abductor muscles or tendons, particularly the gluteus medius and minimus, and can lead to persistent hip pain, muscle weakness, a positive Trendelenburg sign, and impaired walking ability.
Gluteus maximus transfer is a surgical procedure used to restore the function of the hip abductor mechanism in patients with severe abductor insufficiency. This study aims to evaluate the clinical and functional outcomes of gluteus maximus transfer in patients who develop abductor insufficiency following total hip arthroplasty.
The study will assess postoperative improvements in hip function, abductor strength, gait, pain, and patient-reported functional outcomes, as well as the occurrence of postoperative complications. The hypothesis is that gluteus maximus transfer can provide meaningful functional improvement in appropriately selected patients with persistent abductor insufficiency following total hip arthroplasty.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
**Inclusion Criteria**
- Adult patients aged 18 years or older.
- Patients who underwent primary or revision total hip arthroplasty.
- Patients with symptomatic hip abductor insufficiency following total hip arthroplasty.
- Clinical evidence of abductor mechanism deficiency, including abductor weakness, positive Trendelenburg sign, or gait disturbance.
- Patients with irreparable or functionally deficient hip abductor mechanism considered suitable for gluteus maximus transfer.
- Availability of preoperative and postoperative clinical and functional assessment data.
**Exclusion Criteria**
- Active periprosthetic joint infection at the time of the planned procedure.
- Neurological disorders significantly affecting hip abductor function or gait.
- Severe gluteus maximus muscle dysfunction or insufficiency that precludes transfer.
- Severe medical comorbidities contraindicating surgery.
- Inadequate clinical follow-up or missing essential outcome data.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Gluteus Maximus Transfer
Patients with hip abductor insufficiency following total hip arthroplasty undergoing gluteus maximus transfer for reconstruction of the deficient hip abductor mechanism. |
Surgical transfer of the gluteus maximus muscle to reconstruct the deficient hip abductor mechanism in patients with persistent abductor insufficiency following total hip arthroplasty. The procedure aims to improve hip abductor function, pelvic stability, gait, and overall functional outcomes. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Hip Abductor Muscle Strength
Time Frame: Preoperative assessment and 12 months postoperatively.
|
Assessment of hip abductor muscle strength before and after gluteus maximus transfer using manual muscle testing according to the Medical Research Council (MRC) grading scale (0-5). |
Preoperative assessment and 12 months postoperatively.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional Outcome - Harris Hip Score
Time Frame: preoperative baseline to 12 months postoperatively
|
Change in Harris Hip Score from preoperative baseline to 12 months postoperatively to assess hip pain and function. |
preoperative baseline to 12 months postoperatively
|
|
Trendelenburg Sign
Time Frame: preoperative and 12 month postoperative
|
Assessment of the presence or absence of Trendelenburg sign during clinical examination before and 12 month after surgery. |
preoperative and 12 month postoperative
|
|
Pain Assessment
Time Frame: preoperative and 12 months postoperative
|
Change in hip pain intensity measured using the Visual Analog Scale (VAS). |
preoperative and 12 months postoperative
|
|
Postoperative Complications
Time Frame: during the period of follow up 12 months postoperative
|
Documentation of postoperative complications, including persistent abductor weakness, infection, dislocation, wound complications, and revision surgery. |
during the period of follow up 12 months postoperative
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- asy453789
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.